Cantor Fitzgerald Raises Earnings Estimates for GH Research

GH Research PLC (NASDAQ:GHRS) – Stock analysts at Cantor Fitzgerald lifted their FY2025 earnings estimates for GH Research in a report issued on Tuesday, March 4th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will earn ($0.79) per share for the year, up from their prior forecast of ($0.80). Cantor Fitzgerald currently has a “Overweight” rating and a $14.00 price objective on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share.

Several other equities analysts also recently commented on the stock. Stifel Nicolaus boosted their target price on shares of GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. Canaccord Genuity Group decreased their price target on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of GH Research in a research report on Monday, January 27th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, GH Research has a consensus rating of “Buy” and an average target price of $30.60.

GH Research Trading Up 10.9 %

NASDAQ:GHRS opened at $10.41 on Thursday. The stock has a 50-day moving average price of $10.66 and a 200 day moving average price of $9.19. The stock has a market capitalization of $541.61 million, a P/E ratio of -13.18 and a beta of 0.93. GH Research has a 12-month low of $6.00 and a 12-month high of $20.50.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06.

Institutional Investors Weigh In On GH Research

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its holdings in GH Research by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock valued at $508,000 after purchasing an additional 3,092 shares during the last quarter. AdvisorShares Investments LLC boosted its position in shares of GH Research by 15.4% during the fourth quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock valued at $252,000 after buying an additional 4,806 shares during the period. BNP Paribas Financial Markets bought a new position in shares of GH Research during the fourth quarter valued at approximately $44,000. Northern Trust Corp raised its holdings in shares of GH Research by 26.8% in the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock worth $286,000 after buying an additional 8,641 shares during the period. Finally, Two Sigma Investments LP bought a new stake in shares of GH Research during the 4th quarter worth approximately $117,000. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).